Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $7.50 Consensus Target Price from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of equities analysts have weighed in on the company. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Leerink Partners dropped their price target on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, July 2nd. Wedbush began coverage on Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Tuesday. Finally, Wells Fargo & Company assumed coverage on shares of Pyxis Oncology in a research report on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price objective on the stock.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $3.37 on Friday. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55. The stock has a market capitalization of $213.49 million, a PE ratio of -2.39 and a beta of 1.31. The company’s 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $2.01.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, research analysts anticipate that Pyxis Oncology will post -1.22 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently made changes to their positions in PYXS. Renaissance Technologies LLC grew its position in Pyxis Oncology by 22.0% in the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after acquiring an additional 160,300 shares in the last quarter. J. Derek Lewis & Associates Inc. purchased a new stake in Pyxis Oncology during the fourth quarter valued at about $61,000. XTX Topco Ltd lifted its stake in Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after purchasing an additional 271,334 shares during the last quarter. Toronto Dominion Bank bought a new stake in Pyxis Oncology during the fourth quarter worth about $86,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Pyxis Oncology in the 4th quarter worth about $116,000. Institutional investors own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.